Analysis Of Income And Expense [Abstract]

Hyloris Pharmaceuticals SA - Filing #3166256

Concept 2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
2,951,000 EUR
3,096,000 EUR
Material income and expense [abstract]
Research and development expense
10,151,000 EUR
5,056,000 EUR
Miscellaneous other operating income
315,000 EUR
389,000 EUR
Miscellaneous other operating expense
12,000 EUR
5,770,000 EUR
Selling, general and administrative expense [abstract]
General and administrative expense
3,517,000 EUR
2,900,000 EUR
Share of profit (loss) of associates and joint ventures accounted for using equity method [abstract]
Share of profit (loss) of associates and joint ventures accounted for using equity method
130,000 EUR
191,000 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
10,770,000 EUR
10,770,000 EUR
- EUR
- EUR
- EUR
- EUR
11,579,000 EUR
11,579,000 EUR
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent
10,770,000 EUR
11,579,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.